BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Jeff Collins to sit on a panel titled "Investing in Neurotech" at The Neurotech Industry Investing and Partnering Conference in Boston, MA
News | 05. 08. 2008
